Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial

Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial

Abstract Background Diabetes is one of the world’s most widespread conditions, and diabetic patients are among the most likely to engage in fierce battles with this chronic disease. Which group should be added-on as a dual therapy for Egyptian patients with type 2 diabetes and inadequate glycemic ma...

Full description

Bibliographic Details
Main Authors: Haitham G. Zakaraia, Heba F. Salem, Mostafa A. A. Mostafa, Ahmed M. Ali, Hoda M. Rabea
Format: Article
Language:English
Published: SpringerOpen 2023-11-01
Series:Beni-Suef University Journal of Basic and Applied Sciences
Subjects:
T2DM
Sitagliptin
Empagliflozin
Dual therapy
Online Access:https://doi.org/10.1186/s43088-023-00442-0

Similar Items

Similar Items